B · Normal
[Innovent Biologics: Product revenue in the third quarter exceeded RMB 4.7 billion, a year-on-year increase of more than 40%] On October 29, Innovent Biologics announced on the Hong Kong Stock Exchange that in the third quarter of 2026, the company's product revenue exceeded RMB 4.7 billion, a year-on-year increase of more than 40%.
Comments